Alessandro de Carvalho Cruz

Alessandro de Carvalho Cruz

Auto-generated profile, based on publicly available information

Alessandro de Carvalho Cruz

Universidade Federal de Goiás

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
LMLorena A. Moreira
Lorena A. Moreira
LOLanussy P. Oliveira
Lanussy P. Oliveira
MMMarta R. Magalhães
Marta R. Magalhães
SOSayonara A. M. Oliveira
Sayonara A. M. Oliveira
JOJerônimo R. Oliveira-Neto
Jerônimo R. Oliveira-Neto
LCLuiz C. Cunha
Luiz C. Cunha

25 January 2022 in Phytomedicine
Verified
Journal Article
Closed access
DCDanilo Maciel Carneiro
Danilo Maciel Carneiro
TJThiago Veiga Jardim
Thiago Veiga Jardim
YAYmara Cássia Luciana Araújo
Ymara Cássia Luciana Araújo
AAAna Carolina Arantes
Ana Carolina Arantes
ASAndrea Cristina de Sousa
Andrea Cristina de Sousa
PJPaulo César Brandão Veiga Jardim
Paulo César Brandão Veiga Jardim

1 September 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
ACAlessandro de Carvalho Cruz
Alessandro de Carvalho Cruz
ESEunice Mayumi Suenaga
Eunice Mayumi Suenaga
SPShamina Saiyara Prova
Shamina Saiyara Prova
JNJerônimo Raimundo de Oliveira Neto
Jerônimo Raimundo de Oliveira Neto
DIDemian Rocha Ifa
Demian Rocha Ifa
LCLuiz Carlos da Cunha
Luiz Carlos da Cunha

1 February 2021 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ACAlessandro C. Cruz
Alessandro C. Cruz
APAntônio H.S. Pinto
Antônio H.S. Pinto
CCCarla D.D. Costa
Carla D.D. Costa
LOLanussy P. Oliveira
Lanussy P. Oliveira
JOJerônimo R. Oliveira-Neto
Jerônimo R. Oliveira-Neto
LCLuiz C. Cunha
Luiz C. Cunha

10 April 2025 in Biomedical Chromatography
Verified
Journal Article
Open access
LOLanussy Porfiro de Oliveira
Lanussy Porfiro de Oliveira
JNJerônimo Raimundo de Oliveira Neto
Jerônimo Raimundo de Oliveira Neto
TOThiago Sardinha de Oliveira
Thiago Sardinha de Oliveira
LNLara Marques Naves
Lara Marques Naves
SMStefanne Madalena Marques
Stefanne Madalena Marques
LCLuiz Carlos da Cunha
Luiz Carlos da Cunha
A simple and selective high‐performance liquid chromatography bioanalytical method was developed and validated to determine the pharmacokinetic parameters of 5‐[1‐(4‐fluorophenyl)‐1H‐pyrazol‐4‐yl]‐2H‐tetrazole (LQFM020) with promising vasorelaxant, anti‐inflammatory, and antinociceptive properties while verifying its potential hepatic enzyme induction or inhibition. Chromatographic separation was achieved using a reversed‐phase C18 column (ACE, 150 × 4.6 mm, 5 μm) with isocratic elution of a solvent mixture comprising acetonitrile and 0.2% formic acid (30:70, v/v). Detection of LQFM020 and the internal standard, piroxicam, was performed using a photodiode array detector. The method demonstrated excellent linearity (r > 0.998), with precision and accuracy within acceptable limits [intraday precision: 6.1%, interday precision: 9.3%; intraday accuracy: 113.2%, interday accuracy: 107.3%]. Pharmacokinetic studies revealed rapid oral absorption of LQFM020 at doses of 9, 18, and 36 mg/kg, as well as following a single intravenous dose (10 mg/kg). LQFM020 exhibited an absolute bioavailability of 46%, a relatively low apparent volume of distribution, and moderate elimination rates, suggesting extensive plasma protein binding. Additionally, LQFM020 showed no significant effect on the biotransformation of compounds mediated by the cytochrome P450 CYP3A4 enzyme. In conclusion, this new bioanalytical method supports preclinical studies and provides a basis for the utility of LQFM020 as a potential drug candidate.

18 July 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
NANilda Maria Alves
Nilda Maria Alves
MSMarina Silva
Marina Silva
LPLeila Maria Leal Parente
Leila Maria Leal Parente
FUFaculdade de Farmácia / UFG
Faculdade de Farmácia / UFG
ACAlessandro de Carvalho Cruz
Alessandro de Carvalho Cruz
LCLuiz Carlos da Cunha
Luiz Carlos da Cunha
Ethnopharmacological relevance: Diabetes mellitus is a disease that affects approximately 10% of the world population. As it is a chronic disease, several patients search for alternatives to the traditional allopathic treatment, such as medicinal plants. In Brazil, the Aspidosperma subincanum (Guatambu) is one of the vegetal species commercialized in open markets used for diabetes popular treatment. Objective: To perform the phytochemical prospection and pre-clinical assessment of the ethanolic extract from stem bark of A. subincanum bark (EEAS). Material and methods: A. subincanum stem barks were collected in state of Goiás, Brazil and the EEAS was obtained by cold maceration. The phytochemical prospection was performed and acute and subacute toxicity assessments were performed according to OECD guidelines. Results: Phytochemical prospection identified the presence of steroids, triterpenes, saponins, tannins, alkaloids, coumarins, and resins. The acute toxicity showed no death in EEAS doses administered intraperitoneally (500, 1000, and 2000 mg/kg) and orally (5000 mg/kg). The subacute toxicity showed signs of nephrotoxicity, hepatotoxicity, and lung damages in the two highest doses tested (250, 250 mg/kg) in a dose-dependent way. However, the satellite group showed reversion of the lesions after 30 days of EEAS interruption. Conclusion: The acute toxicity of EEAS suggests an LD50 > 5000 mg/kg. The oral use of EEAS during a short period (30 days) or more can be hazardous at doses similar to that tested in this study and may represent a risk for those who consume this kind of extract as a medicinal plant.